A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With a Checkpoint Inhibitor for Subjects With Advanced Solid Tumors
Sponsor: Adanate, Inc
Terminated
Internal company decision (non-safety related)
Other Solid Tumor, Adult trials with similar outcome
This PHASE1 trial investigates Solid Tumor, Adult and is currently terminated or withdrawn. Adanate, Inc leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Feb 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Oct 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Nov 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adanate, Inc
For direct contact, visit the study record on ClinicalTrials.gov .